UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 84

Sortiert nach

Translating cancer research into targeted therapeutics

Nature (London), 2010-09, Vol.467 (7315), p.543-549

2010

Volltextzugriff (PDF)

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

Annals of oncology, 2010-01, Vol.21 (1), p.109-113

2010

Volltextzugriff (PDF)

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

Annals of oncology, 2013-07, Vol.24 (7), p.1807-1812

2013

Volltextzugriff (PDF)

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

European journal of cancer (1990), 2014-01, Vol.50 (1), p.78-84

2014

Volltextzugriff (PDF)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Annals of oncology, 2013-09, Vol.24 (9), p.2402-2408

2013

Volltextzugriff (PDF)

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

European journal of cancer (1990), 2012-01, Vol.48 (1), p.85-93

2012

Volltextzugriff (PDF)

Molecular alterations and emerging targets in castration resistant prostate cancer

European journal of cancer (1990), 2014-03, Vol.50 (4), p.753-764

2014

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Cancer chemotherapy and pharmacology, 2011-06, Vol.67 (6), p.1273-1279

2011

Volltextzugriff (PDF)

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

Annals of oncology, 2014-02, Vol.25 (2), p.429-434

2014

Volltextzugriff (PDF)

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer

Annals of oncology, 2010-09, Vol.21 (9), p.1851-1857

2010

Volltextzugriff (PDF)

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Annals of oncology, 2014-03, Vol.25 (3), p.657-662

2014

Volltextzugriff (PDF)

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Annals of oncology, 2009-01, Vol.20 (1), p.27-33

2009

Volltextzugriff (PDF)

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Annals of oncology, 2013-04, Vol.24 (4), p.1017-1025

2013

Volltextzugriff (PDF)

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Annals of oncology, 2012-08, Vol.23 (8), p.1968-1973

2012

Volltextzugriff (PDF)

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

Annals of oncology, 2012-05, Vol.23 (5), p.1241-1249

2012

Volltextzugriff (PDF)

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2014-11, Vol.74 (5), p.1039-1046

2014

Volltextzugriff (PDF)

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

Annals of oncology, 2004-12, Vol.15 (12), p.1825-1833

2004

Volltextzugriff (PDF)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

British journal of cancer, 2008-03, Vol.98 (5), p.894-899

2008

Volltextzugriff (PDF)

The oral fluorinated pyrimidines

Investigational new drugs, 2001-02, Vol.19 (1), p.41-59

2001

Volltextzugriff (PDF)

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

British journal of cancer, 2002-03, Vol.86 (5), p.680-685

2002

Volltextzugriff (PDF)

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Annals of oncology, 2006-08, Vol.17 (8), p.1313-1319

2006

Volltextzugriff (PDF)

Metastatic extragonadal seminoma associated with cardiac transplantation

Annals of oncology, 2000-06, Vol.11 (6), p.749-752

2000

Volltextzugriff (PDF)

Phase I Study of ONO-4007, a Synthetic Analogue of the Lipid A Moiety of Bacterial Lipopolysaccharide

Clinical cancer research, 2000-02, Vol.6 (2), p.397-405

2000

Volltextzugriff (PDF)

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

BJU international, 2005-12, Vol.96 (9), p.1241-1246

2005

Volltextzugriff (PDF)

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

Clinical cancer research, 2004-11, Vol.10 (22), p.7555-7565

2004

Volltextzugriff (PDF)

1 – 25 von 84

Suche als RSS-Feed

Aktive Filter

ThemaPharmacology. Drug Treatments

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(80)

Publikationsform

Artikel
(84)

Sprache

Englisch
(84)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(84)
Medical Sciences
(84)
Science & Technology
(69)
Life Sciences & Biomedicine
(68)
Humans
(66)
Male
(54)
Antineoplastic Agents
(51)
Aged
(48)
Middle Aged
(45)
Oncology
(44)
Adult
(31)
Female
(30)
Tumors
(30)
Aged, 80 And Over
(22)
Chemotherapy
(19)
Blood. Blood Coagulation. Reticuloendothelial System
(17)
Gynecology. Andrology. Obstetrics
(16)
Nephrology. Urinary Tract Diseases
(16)
Tumors Of The Urinary System
(16)

14 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Translating cancer research into targeted therapeutics

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC)

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer

Molecular alterations and emerging targets in castration resistant prostate cancer

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer

Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience

Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy

A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors

Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours

The oral fluorinated pyrimidines

A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer

A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours

Metastatic extragonadal seminoma associated with cardiac transplantation

Phase I Study of ONO-4007, a Synthetic Analogue of the Lipid A Moiety of Bacterial Lipopolysaccharide

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

Aktive Filter

Suchergebnisse filtern